Molecular Hydrogen Therapy: Evidence Review and the Science Behind (2026)
A comprehensive, peer-reviewed synthesis of preclinical and clinical evidence for H₂ therapy across 20 disease categories — 2026 Update
Abstract
Molecular hydrogen (H₂) has emerged over the past two decades as a uniquely versatile therapeutic agent, distinguished by its ability to selectively scavenge cytotoxic reactive oxygen species (ROS) while crossing all biological barriers, including the blood-brain barrier. Since the landmark 2007 Nature Medicine publication, more than 5,000 papers and over 100 registered clinical trials have examined H₂ across conditions spanning neurodegeneration, cancer, cardiovascular disease, metabolic syndrome, inflammatory disorders, and respiratory illness. This updated review synthesises preclinical and clinical evidence by category, incorporates results from the HYBRID II randomised controlled trial (2023) and a 2026 respiratory medicine meta-review, updates the Parkinson’s disease evidence base to include null results from a large 180-patient RCT, and expands mechanistic understanding beyond the simple antioxidant paradigm to include Nrf2 activation, NF-κB suppression, mitochondrial protection, gut microbiota modulation, and immune cell polarisation. H₂ therapy maintains an excellent safety profile with no known toxicity at therapeutic doses. Evidence quality ranges from compelling (antioxidant and anti-inflammatory effects) to preliminary (cancer adjuvant, neurodegenerative disease). Larger, adequately-powered phase III trials are needed before routine clinical translation.
1. Background & History
We were sceptical about molecular hydrogen until we conducted our own literature review. Surprisingly, a growing body of peer-reviewed evidence reveals that this simple, ancient molecule — the most abundant in the Universe — possesses remarkable and selective biological activity. Hydrogen (H₂) is an odourless, colourless, tasteless, and non-toxic diatomic gas. Yet it is now the subject of one of medicine’s most rapidly expanding research programmes.
The therapeutic relevance of endogenous hydrogen was first proposed in 1988, when investigators hypothesised that molecular hydrogen produced in large quantities as a by-product of colonic fermentation of dietary fibre may serve as a potent antioxidant, contributing to the protective effects of high-fibre diets against chronic disease (Med Hypotheses. 1988). Decades later, in an earlier clinical application, hydrogen was administered therapeutically to three deep-sea divers in the early 1990s to counteract high-pressure neurological syndrome, representing its first documented use in humans.
The field was transformed by Ohsawa et al. in 2007, who published in Nature Medicine the now-landmark finding that inhaled hydrogen gas acts as a selective antioxidant, protecting the brain from ischaemic injury in rats by neutralising hydroxyl radicals (•OH) and peroxynitrite (ONOO⁻) — two of the most cytotoxic ROS species — without disrupting beneficial ROS involved in signalling (Nat Med. 2007). This selectivity distinguishes H₂ from non-selective antioxidants such as vitamin C or N-acetylcysteine.
Since that publication, the field has expanded dramatically. As of 2026, a PubMed search for “molecular hydrogen” returns over 5,000 results, with more than 100 clinical trials registered globally. The effects of hydrogen have been studied in at least 63 disease categories, spanning neurodegeneration, metabolic disease, cancer, respiratory illness, inflammatory conditions, ageing, and more.
2. Mechanisms of Action
Early research framed H₂ primarily as an antioxidant. The current understanding is substantially more nuanced. Molecular hydrogen is now recognised as a pleiotropic signalling molecule whose biological effects are mediated through multiple, partly interconnected pathways. Its small molecular size (molecular weight 2 g/mol) enables it to penetrate biological membranes, cross the blood-brain barrier, and reach intracellular compartments including the mitochondria — making it unique among therapeutic gases.
3. Long COVID & Chronic Fatigue Syndrome
One of the most actively researched emerging applications of hydrogen therapy involves post-viral syndromes, particularly long COVID (Post-Acute Sequelae of SARS-CoV-2, PASC) and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Both conditions are characterised by systemic inflammation, mitochondrial dysfunction, and oxidative stress — the precise targets of H₂ therapy.
A randomised controlled trial in acute post-COVID-19 patients found that hydrogen gas inhalation produced statistically significant improvements in physical and respiratory function compared with control, including improved 6-minute walk distance and pulmonary function parameters. No adverse events were observed.
A systematic literature review concluded that hydrogen gas is a promising medical gas candidate for the treatment of chronic fatigue syndrome, citing its anti-inflammatory and mitochondrial-protective mechanisms as particularly relevant to the pathophysiology of ME/CFS.
The largest hydrogen therapy trial in infectious disease to date, the Hydro-Covid Phase 3 trial enrolled 700 COVID-19 outpatients in a randomised, triple-blinded, adaptive, placebo-controlled design. Participants were randomised between January 2021 and March 2022. Results are available as a preprint and under peer review at time of publication.
Griffith University researchers identified similar brainstem structural abnormalities in both ME/CFS and long COVID patients, supporting the hypothesis that shared neuroinflammatory mechanisms underlie both conditions — and potentially strengthening the rationale for hydrogen therapy, which targets neuroinflammation, in long COVID management.
4. Cancer — Adjuvant Therapy
Hydrogen therapy in oncology is one of the most actively studied applications, with over 600 publications retrieved from PubMed, Google Scholar, and Cochrane at the time of writing. The primary hypotheses under investigation are that H₂: (1) reduces tumour-promoting oxidative stress; (2) exerts direct anti-proliferative and pro-apoptotic effects on cancer cells; and (3) mitigates the oxidative toxicity of conventional chemotherapy and radiotherapy without compromising their anti-tumour efficacy.
The first systematic review to comprehensively evaluate molecular hydrogen in cancer (Cochrane, PubMed, Google Scholar) included 27 eligible articles from 677 retrieved. The authors concluded that H₂ plays a promising therapeutic role both as an independent therapy and as an adjuvant in combination therapy, with overall improvements observed in survivability, quality of life, blood parameters, and tumour reduction. Studies spanned colorectal, liver, pancreatic, lung, and haematological malignancies.
Proposed anti-cancer mechanisms include selective ROS reduction in the tumour microenvironment, upregulation of tumour suppressor gene expression, modulation of the PPARα pathway (reducing fatty acid oxidation in cancer cells), and enhancement of NK cell and CD8+ T-cell anti-tumour activity through immune polarisation effects. It is important to note that the majority of evidence remains preclinical; well-designed phase III trials in specific cancer subtypes are needed.
5. Neuroprotection, Stroke & Cardiac Arrest
The original 2007 Nature Medicine publication demonstrated that inhaled H₂ protected the rat brain from ischaemia-reperfusion injury by scavenging cytotoxic ROS. This sparked a sustained programme of translational research in stroke, post-cardiac arrest syndrome, and neonatal brain injury.
Foundational study demonstrating that molecular hydrogen selectively reduces cytotoxic ROS in rat brain ischaemia, establishing the antioxidant mechanism of hydrogen therapy and triggering worldwide research interest.
The first human pilot study of hydrogen in stroke patients found that intravenous hydrogen solution was safe and produced a mild antioxidant effect, with no adverse events. Sample size was insufficient for efficacy conclusions.
A randomised controlled study found hydrogen gas inhalation treatment to be safe and effective in patients with acute ischaemic stroke (cerebral infarction), with significant improvements in neurological scores compared to controls.
The HYBRID II trial is the most rigorous H₂ RCT completed to date. Conducted across 15 Japanese hospitals (2017–2021), it enrolled 73 adult comatose patients following cardiogenic out-of-hospital cardiac arrest. Patients received either 2% H₂ in oxygen or oxygen alone for 18 hours, combined with targeted temperature management (TTM). Good neurological outcomes at 90 days were achieved in 56% of the hydrogen group vs. 39% of controls — a clinically meaningful 17-percentage-point difference. However, this did not reach statistical significance (RR 0.72; 95% CI 0.46–1.13; P = 0.15), as the trial was terminated prematurely due to COVID-19 pandemic enrolment restrictions (429 screened; only 73 of the planned 360 enrolled). The trial confirmed the safety and feasibility of hydrogen gas inhalation in mechanically ventilated, critically ill patients. A 2024 post-hoc analysis further explored a synergistic benefit when H₂ was combined with deeper TTM (32–34°C).
6. Parkinson’s Disease Evidence Updated 2026
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterised by dopaminergic neuronal loss in the substantia nigra, driven substantially by mitochondrial dysfunction and oxidative stress — both direct targets of H₂. Preclinical evidence in MPTP mouse models showed that hydrogen water reduced dopaminergic neuronal loss. Human trials have produced mixed results.
In a small double-blind placebo-controlled pilot study, levodopa-treated Parkinson’s patients who drank 1 litre/day of hydrogen-rich water for 48 weeks showed improvement in total UPDRS scores (−5.7 ± 8.4), while the placebo group worsened (+4.1 ± 9.2; P<0.05). No adverse effects were reported. These encouraging results prompted a larger confirmatory trial.
The larger confirmatory RCT (n=179) failed to replicate the pilot study findings. No statistically significant difference in UPDRS scores was observed between the hydrogen water and placebo water groups over the study duration. This null result substantially tempers the earlier optimism and underscores the need for caution in interpreting small pilot trials.
A randomised double-blind placebo-controlled pilot trial of hydrogen gas inhalation (6.5% H₂, twice daily for 16 weeks) in levodopa-treated Parkinson’s patients found no significant difference in total UPDRS scores between the H₂ and control groups. No adverse events were recorded. The treatment was safe and well-tolerated, but the trial was underpowered.
7. Chemoprotective & Radioprotective Effects
Ionising radiation and cytotoxic chemotherapy exert their cancer-killing effects partly via oxidative mechanisms, but simultaneously cause collateral oxidative damage to normal tissues. The only FDA-approved radioprotectant — amifostine — has significant limitations including short duration of protection, intravenous administration requirement, and considerable toxicity. H₂ presents as a potentially superior alternative, given its broad bioavailability, absence of known toxicity, and evidence of selective action that spares cancer-killing ROS.
In 49 patients undergoing radiotherapy for liver cancer, drinking 1.5–2 L/day of hydrogen water improved quality of life and appetite scores compared to controls. Critically, hydrogen water reduced oxidative stress markers without compromising the cancer-killing effects of radiation, suggesting therapeutic selectivity.
In 152 colorectal cancer patients undergoing chemotherapy, the hydrogen-rich water group showed a significant protective effect against chemotherapy-related liver injury, as measured by liver enzyme levels, compared to the control group.
A comprehensive review of H₂ as a radioprotectant covered in vitro, in vivo, and clinical findings. It concluded that H₂ can be easily applied with minimal adverse effects and demonstrates efficacy as a potential radioprotective agent across multiple delivery modes. Unlike amifostine, hydrogen does not appear to compromise anti-tumour radiation effects at therapeutic doses.
8. Metabolic Syndrome & Diabetes
Drinking 900 mL/day of hydrogen water for 8 weeks decreased LDL cholesterol, improved glucose tolerance, and reduced insulin resistance in 36 patients with type 2 diabetes or pre-diabetes.
Patients with metabolic syndrome who drank 1.5–2 L/day of hydrogen water for 8 weeks demonstrated an 8% increase in HDL-cholesterol and a 13% decrease in the total cholesterol/HDL ratio from baseline to week 4, suggesting a beneficial lipid profile effect.
9. Musculoskeletal Disorders 2026 Review
A 2026 evidence-based review and critical analysis (PubMed, EMBASE, Cochrane, through April 2025) identified 45 eligible studies examining H₂ therapy in musculoskeletal conditions. Preclinical models consistently demonstrated reductions in ROS, inflammatory cytokines, and improved cell viability. Clinical trials reported symptomatic relief in osteoarthritis, decreased Disease Activity Score-28 (DAS28) in rheumatoid arthritis, and accelerated clearance of exercise-induced muscle damage markers. The review noted methodological heterogeneity across delivery methods (hydrogen-rich water, gas inhalation, hydrogen-rich saline infusion), limiting direct comparison.
Twenty patients with rheumatoid arthritis drank 0.5 L/day of hydrogen water for 4 weeks. All patients with early RA achieved remission, and 20% became symptom-free. Oxidative stress markers were significantly reduced.
In 10 young male athletes, drinking hydrogen water before exercise reduced blood lactate concentration during heavy exercise and decreased muscle fatigue scores, suggesting a role in sports performance recovery.
In a 2-week crossover RCT, cyclists drinking 2 L/day of hydrogen water maintained higher peak power output during sprint intervals and reported lower perceived exertion compared to the placebo period.
A 2025 case report documented clinical improvement in a 66-year-old female with RA who developed severe methotrexate-induced myelosuppression. Following initiation of molecular hydrogen therapy, laboratory parameters normalised and flow cytometry demonstrated progressive increases in PD-1+ T-cell subsets and memory/activated regulatory T-cells, suggesting immunomodulatory activity relevant to RA management.
10. Respiratory Disease 2026 Review
A major 2026 review of molecular hydrogen in respiratory medicine (covering MEDLINE, EMBASE, Google Scholar through June 2025) found that preclinical studies consistently demonstrated H₂ protective effects in models of COPD, asthma, pulmonary fibrosis, pulmonary hypertension, acute lung injury, lung cancer, and COVID-19. Mechanistically, H₂ selectively scavenges hydroxyl radicals and peroxynitrite, protects mitochondrial function, activates Nrf2-mediated antioxidant responses, inhibits inflammasome and NF-κB signalling, and modulates immune cell polarisation and apoptosis pathways. Early clinical trials and case reports support improvements in oxygenation, exercise tolerance, and inflammatory markers, alongside a strong safety profile. The authors concluded that future research must focus on multicentre randomised trials, dose–response studies, and device integration to establish H₂’s role in evidence-based respiratory care.
Workers exposed to air pollution randomised to inhale a hydrogen/oxygen mixture (66.67%:33.33%) for 1 hour/day for 30 days showed significant protection against haze-related lung injury and improvements in respiratory symptoms including cough, compared with the nitrogen/oxygen control group.
11. Skin Health, Anti-Aging & Longevity
Intravenous hydrogen solution safely improved skin redness, inflammation, and pain in 4 patients. Erythema resolved within days of treatment and did not recur during follow-up.
Bathing in hydrogen water for 3 months noticeably reduced visible skin wrinkles in 6 participants. Mechanistic follow-up demonstrated that hydrogen water could also boost collagen production, reduce UV-induced oxidative damage, and act as an antioxidant in skin cell cultures.
Published in Scientific Reports, a clinical trial of hydrogen-water bathing therapy over 8 weeks demonstrated fulfillment of an unmet therapeutic need in patients with chronic inflammatory skin disease including psoriasis, with significant improvements in PASI scores.
A 2022 review of H₂ and ageing biology synthesised evidence for hydrogen’s role in maintaining genomic stability, mitigating cellular senescence, histone modification, telomere maintenance, and proteostasis. The review found that hydrogen may prevent inflammation and regulate mTOR, autophagy, apoptosis, and mitochondrial function — all hallmarks of ageing. Clinical applications proposed include prevention and treatment of neurodegenerative disorders, cardiovascular disease, pulmonary disease, diabetes, and cancer. Separately, hydrogen was shown to prolong stem cell life by reducing oxidative stress.
12. Other Organ Systems
Eye Health
Hydrogen-loaded eye drops aided recovery from acute glaucomatous eye injuries in rats, protecting retinal ganglion cells through antioxidant action. Separately, a hydrogen solution reduced pathological blood vessel growth in chemical burn models. A 2021 randomised crossover clinical trial (Keio University School of Medicine) found that molecular hydrogen promoted tear secretion and protected lacrimal glands, with implications for dry eye disease.
Kidney Protection
In a study of 21 kidney failure patients on dialysis, adding hydrogen to the dialysis solution reduced inflammatory markers and high blood pressure, suggesting a potential adjunct role in renal replacement therapy.
Liver Protection
In 60 patients with chronic Hepatitis B, hydrogen water as an add-on to standard antiviral treatment was safe and significantly improved liver function tests and reduced oxidative stress markers compared with controls.
Oral Health
Drinking hydrogen water 4–5 times daily improved gum health in 13 patients with gingivitis after 8 weeks, boosted antioxidant capacity in blood, and enhanced outcomes of conventional periodontal therapy. In vitro evidence also suggests H₂ may inhibit Streptococcus mutans and other cariogenic bacteria.
Transplant Organ Preservation
Hydrogen water demonstrated the ability to reduce ischaemia-reperfusion injury during organ storage without toxic effects, with potential implications for expanding the transplant organ donor pool by reducing discard rates from preservation injury.
Wound Healing
Tube-fed hydrogen water reduced pressure ulcer wound size and accelerated recovery in elderly patients, with effects attributed to local reduction in oxidative stress and inflammatory cytokines.
Mitochondrial Disease
In 41 patients with muscle diseases including mitochondrial myopathies, drinking 0.5–1 L/day of hydrogen water improved mitochondrial function markers. Given the central role of mitochondrial dysfunction in numerous chronic diseases, this application warrants further investigation.
13. Safety, Dosage & Side Effects
Molecular hydrogen has one of the most favourable safety profiles of any therapeutic gas investigated to date. It is not toxic even at high concentrations, and no serious adverse events attributable to H₂ itself have been reported across any human trial.
Clinical Dosage
In the majority of clinical trials, hydrogen water was consumed at 0.5–2 L/day (hydrogen concentration approximately 0.8–1.6 ppm). For hydrogen gas inhalation, concentrations of 2–4% H₂ in oxygen or air have been used. After oral intake of hydrogen water, approximately 40% of the H₂ is absorbed across the gastrointestinal tract in oral administration studies. Optimal dosing remains an active area of investigation; dose-response studies are a priority identified in recent reviews.
Administration Routes
Hydrogen can be administered via: (1) hydrogen-rich water (most widely studied and practical); (2) inhalation of H₂ gas (used in critical care settings); (3) intravenous hydrogen-rich saline (used in some Japanese clinical trials); (4) hydrogen-rich baths (studied for dermatological applications); and (5) hydrogen eye drops (ophthalmological use). Each route has distinct pharmacokinetic characteristics.
14. Evidence Summary Table
The following table summarises the quality and direction of current evidence for hydrogen therapy across key clinical categories, based on the totality of published studies reviewed in this article.
| Clinical Area | Best Evidence Level | No. Human Studies | Direction | Status |
|---|---|---|---|---|
| Antioxidant / ROS Reduction | Multiple RCTs + mechanistic | 20+ | Positive | Established |
| Anti-inflammatory Effects | Multiple RCTs | 15+ | Positive | Established |
| Post-COVID-19 / Respiratory Function | RCT (n=60) + Phase 3 (n=700, pending) | 4 | Positive | Emerging |
| Cancer (Adjuvant) | Systematic Review (27 studies) | 27 | Promising | Investigational |
| Radioprotection | RCT + Review | 5+ | Positive | Emerging |
| Stroke / Ischaemia | RCT (2017) | 3 | Positive | Emerging |
| Post-Cardiac Arrest (HYBRID II) | Multicentre RCT (n=73; underpowered) | 2 | Mixed / Trending | Phase III Needed |
| Parkinson’s Disease | RCT (n=179; null) + pilot (positive) | 3 | Inconclusive | Requires Replication |
| Metabolic Syndrome / Diabetes | RCT (n=36) | 4 | Positive | Emerging |
| Rheumatoid Arthritis | Open-label + RCT + 2026 review | 5 | Positive | Emerging |
| Exercise / Muscle Fatigue | DB-CT + small RCTs | 5 | Positive | Emerging |
| Skin Health / Psoriasis | Clinical trial (Sci Rep 2018) | 4 | Positive | Emerging |
| Hepatitis B / Liver Protection | Controlled study (n=60) | 3 | Positive | Emerging |
| Kidney / Dialysis | Controlled study (n=21) | 2 | Positive | Preliminary |
| Oral Health / Gingivitis | Controlled study (n=13) | 2 | Positive | Preliminary |
| Mitochondrial Disease | Open-label (n=41) | 1 | Positive | Preliminary |
| MCI / Cognitive Decline | RCT (n=73; null at 1 year) | 2 | Null (1 year) | Requires Study Design Review |
Medical Disclaimer: This review is for informational purposes only. Hydrogen therapy is investigational for most indications discussed. It should not replace established medical treatment. Patients with active medical conditions should consult their physician before initiating hydrogen therapy.
Editorial Standard: This article follows a peer-review journal format with full citation of primary literature. All studies cited are accessible via hyperlink to PubMed abstracts or full-text publications.
15. Selected Key References
- Ohsawa I, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med. 2007;13:688–694. [PubMed]
- Ichihara M, et al. Beneficial biological effects and the underlying mechanisms of molecular hydrogen. Med Gas Res. 2015. [PMC]
- Tamura T, et al. (HYBRID II Study Group). Efficacy of inhaled hydrogen on neurological outcome following brain ischaemia during post-cardiac arrest care: a multi-centre, randomised, double-blind, placebo-controlled trial. EClinicalMedicine (Lancet). 2023;58:101907. [Full Text]
- Yoritaka A, et al. Pilot study of H₂ therapy in Parkinson’s disease: a randomized double-blind placebo-controlled trial. Mov Disord. 2013. [PubMed]
- Yoritaka A, et al. Large-scale RCT of hydrogen water in Parkinson’s disease: null result. [Registered trial; results documented in ALZDISCOVERY cognitive vitality report.] [Review PDF]
- Yoritaka A, et al. Randomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson’s disease: a pilot study. Neurol Sci. 2021. [PMC]
- Chuang YT, et al. Molecular hydrogen therapy in respiratory diseases: mechanisms, evidence, and technical considerations. Published online Mar 2026. [Full Text]
- Mohd Noor MNZ, et al. A systematic review of molecular hydrogen therapy in cancer management. Asian Pac J Cancer Prev. 2023. [PubMed]
- Abraini JH, et al. Therapeutic use of hydrogen gas in deep-sea diving. J Appl Physiol. 1994. [PubMed]
- Ishibashi T, et al. Consumption of hydrogen-rich water reduces oxidative stress and disease activity in patients with rheumatoid arthritis. Med Gas Res. 2012. [PMC]
- Kajiyama S, et al. Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance. Nutr Res. 2008. [PubMed]
- Nakao A, et al. Effectiveness of hydrogen-rich water on antioxidant status of subjects with potential metabolic syndrome. BMC Proceedings. 2010. [PMC]
- Mancebo JG, et al. Performance of unmodified mechanical ventilators with 2% hydrogen gas mixtures. Respir Care. 2025;70(4):377–383. [Ref]
- Jeyaraman N, et al. Molecular hydrogen therapy in musculoskeletal conditions: An evidence-based review and critical analysis. World J Orthop. 2026. [PMC]
- Ostojic SM. Molecular hydrogen therapy in rheumatoid arthritis: immune modulation and myelosuppression relief. In Vivo. 2025;39(4). [Full Text]
- Ionescu L, et al. Molecular hydrogen therapy — a review on clinical studies and outcomes. Molecules. 2023;28:7785. [PMC]
- Zhao S, et al. Hydrogen-rich water bathing therapy for psoriasis. Sci Rep. 2018. [Nat Sci Rep]
- Kurokawa M, et al. Randomized crossover trial on tear secretion promotion and lacrimal gland protection by molecular hydrogen. Sci Rep. 2021. [PMC]
- Neale RJ. Hypothesis: hydrogen, produced by bacteria from dietary fibre, as a major player in anti-aging. Med Hypotheses. 1988. [PubMed]
- Li Q, et al. Hydrogen water intake via tube feeding reduced pressure ulcer. Med Gas Res. 2013. [PubMed]
.png)
Comments